SHA: 600196

Explore the latest insights on SHA: 600196 and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of SHA: 600196’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Yifan Pharmaceutical Secures China Rights to Boryung's Taxotere – Docetaxel Injection Commercialization Deal Covers Promotion, Distribution and Market Operations
CompanyDeals

Yifan Pharmaceutical Secures China Rights to Boryung’s Taxotere – Docetaxel Injection Commercialization Deal Covers Promotion, Distribution and Market Operations

Yifan Pharmaceutical Co., Ltd. (SHE: 002019) and Boryung Corporation (KRX: 003850) of South Korea announced a partnership agreement under which Yifan Pharmaceutical has obtained the general agency rights for Taxotere…

Novo Nordisk's Once‑Weekly CagriSema Proves Superior to Tirzepatide in Head‑to‑Head Weight Loss Trial – REDEFINE 9 Delivers 21.0% Reduction vs Placebo

Novo Nordisk’s Once‑Weekly CagriSema Proves Superior to Tirzepatide in Head‑to‑Head Weight Loss Trial – REDEFINE 9 Delivers 21.0% Reduction vs Placebo

Biokin's Bispecific ADC Izalontamab Bretecan Wins Eighth Breakthrough Therapy Designation in China – PD-1 Combo Targets First-Line PD-L1-Positive TNBC

Biokin’s Bispecific ADC Izalontamab Bretecan Wins Eighth Breakthrough Therapy Designation in China – PD-1 Combo Targets First-Line PD-L1-Positive TNBC

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Company

Shanghai Fosun Pharmaceutical Reports 5.31% YOY Revenue Growth and Strong R&D Investment in 2024H1 Report

CompanyDeals

Fosun Pharma’s Privatization of Henlius Includes Cash and Share Offers, Aims for Full Equity Control

Company

Fosun Pharma’s West African Project Nears First-Phase Completion, Aims for 5 Billion Drug Units Annually

CompanyDeals

Fosun Pharma and Kite Pharma Inject USD 28.5 Million into Joint Venture for CAR-T Therapy Development

CompanyDrug

Shanghai Fosun Pharmaceutical Gets NMPA Green Light for FH-2001 and Serplulimab Combo Clinical Trial

CompanyDeals

Fosun Pharma to Take Henlius Private in Deal Valued at HKD 5.407 Billion

CompanyDeals

Shanghai Fosun Pharmaceutical Sells Stake in Gland Pharma for USD 211 Million

CompanyDrug

Fosun Pharma’s FCN-159 Receives Priority Review Status from NMPA for Pediatric Neurofibromatosis

Show More